Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Fractyl has built its patent portfolio since 2011, and its IP estate now includes 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. The two newly issued patents further reinforce the Company's leadership position in duodenal resurfacing applications. U.S. Patent No. 12,329,439, issued June 17, 2025, and U.S. Patent No. 12,303,185, issued May 20, 2025, both titled "Electrical energy ablation systems, devices and method ...